BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

771 related articles for article (PubMed ID: 18163003)

  • 1. Anti-vascular endothelial growth factor therapy for ocular neovascular disease.
    Andreoli CM; Miller JW
    Curr Opin Ophthalmol; 2007 Nov; 18(6):502-8. PubMed ID: 18163003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease.
    Tolentino M
    Surv Ophthalmol; 2011; 56(2):95-113. PubMed ID: 21335144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration.
    Eyetech Study Group
    Retina; 2002 Apr; 22(2):143-52. PubMed ID: 11927845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Updates on the Management of Ocular Vasculopathies with VEGF Inhibitor Conbercept.
    Liu H; Ma Y; Xu HC; Huang LY; Zhai LY; Zhang XR
    Curr Eye Res; 2020 Dec; 45(12):1467-1476. PubMed ID: 32631094
    [No Abstract]   [Full Text] [Related]  

  • 5. Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration.
    Ciulla TA; Rosenfeld PJ
    Curr Opin Ophthalmol; 2009 May; 20(3):166-74. PubMed ID: 19381089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antivascular endothelial growth factors in age-related macular degeneration.
    Schmidt-Erfurth U; Pollreisz A; Mitsch C; Bolz M
    Dev Ophthalmol; 2010; 46():21-38. PubMed ID: 20703030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema.
    Emerson MV; Lauer AK
    BioDrugs; 2007; 21(4):245-57. PubMed ID: 17628122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration.
    Ciulla TA; Rosenfeld PJ
    Curr Opin Ophthalmol; 2009 May; 20(3):158-65. PubMed ID: 19417570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fellow Eye Comparisons for 7-Year Outcomes in Ranibizumab-Treated AMD Subjects from ANCHOR, MARINA, and HORIZON (SEVEN-UP Study).
    Bhisitkul RB; Desai SJ; Boyer DS; Sadda SR; Zhang K
    Ophthalmology; 2016 Jun; 123(6):1269-77. PubMed ID: 26996339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of neovascular glaucoma. Etiopathogenesis and treatment.
    Dumbrăveanu L; Cușnir V; Bobescu D
    Rom J Ophthalmol; 2021; 65(4):315-329. PubMed ID: 35087972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of vascular endothelial growth factor in ocular angiogenesis.
    Shams N; Ianchulev T
    Ophthalmol Clin North Am; 2006 Sep; 19(3):335-44. PubMed ID: 16935208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia.
    Zhu Y; Zhang T; Xu G; Peng L
    Cochrane Database Syst Rev; 2016 Dec; 12(12):CD011160. PubMed ID: 27977064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profile of conbercept in the treatment of neovascular age-related macular degeneration.
    Lu X; Sun X
    Drug Des Devel Ther; 2015; 9():2311-20. PubMed ID: 25960634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
    Ferrara N; Damico L; Shams N; Lowman H; Kim R
    Retina; 2006 Oct; 26(8):859-70. PubMed ID: 17031284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review.
    Kourlas H; Abrams P
    Clin Ther; 2007 Sep; 29(9):1850-61. PubMed ID: 18035187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Intraocular antiangiogenic drugs in clinical application advantages and disadvantages].
    Li XX
    Zhonghua Yan Ke Za Zhi; 2012 Oct; 48(10):870-3. PubMed ID: 23302238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiangiogenic therapy for ischemic retinopathies.
    Al-Latayfeh M; Silva PS; Sun JK; Aiello LP
    Cold Spring Harb Perspect Med; 2012 Jun; 2(6):a006411. PubMed ID: 22675660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis.
    Pham B; Thomas SM; Lillie E; Lee T; Hamid J; Richter T; Janoudi G; Agarwal A; Sharpe JP; Scott A; Warren R; Brahmbhatt R; Macdonald E; Straus SE; Tricco AC
    BMJ Open; 2019 May; 9(5):e022031. PubMed ID: 31142516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current therapeutic approaches in neovascular age-related macular degeneration.
    Nguyen DH; Luo J; Zhang K; Zhang M
    Discov Med; 2013 Jun; 15(85):343-8. PubMed ID: 23819948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-VEGF therapy: comparison of current and future agents.
    Pieramici DJ; Rabena MD
    Eye (Lond); 2008 Oct; 22(10):1330-6. PubMed ID: 18497829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.